

NEWS 46 Feb 24 TEMA now available on STN  
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 48 Feb 26 PCTFULL now contains images  
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:44:26 ON 11 MAR 2003

=> file .jacob  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:45:08 ON 11 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 08:45:08 ON 11 MAR 2003

FILE 'EMBASE' ENTERED AT 08:45:08 ON 11 MAR 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 08:45:08 ON 11 MAR 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> biomarker and (urine or serum) and pulmonary  
L1 91 FILE CAPLUS  
L2 47 FILE MEDLINE  
L3 38 FILE EMBASE  
L4 137 FILE BIOSIS

TOTAL FOR ALL FILES

L5 313 BIOMARKER AND (URINE OR SERUM) AND PULMONARY

=> 15 and cadherin

L6 0 FILE CAPLUS  
L7 0 FILE MEDLINE  
L8 0 FILE EMBASE  
L9 0 FILE BIOSIS

TOTAL FOR ALL FILES

L10 0 L5 AND CADHERIN

=> 15 and FEV1

L11 1 FILE CAPLUS  
L12 2 FILE MEDLINE  
L13 1 FILE EMBASE  
L14 3 FILE BIOSIS

TOTAL FOR ALL FILES

L15 7 L5 AND FEV1

=> dup rem

ENTER L# LIST OR (END):115

PROCESSING COMPLETED FOR L15

L16 4 DUP REM L15 (3 DUPLICATES REMOVED)

=> d 116 ibib abs total

L16 ANSWER 1 OF 4 MEDLINE DUPLICATE 1  
ACCESSION NUMBER: 2002404352 MEDLINE  
DOCUMENT NUMBER: 22148611 PubMed ID: 12153756  
TITLE: Environmental tobacco smoke exposure and **pulmonary**  
function among adults in NHANES III: impact on the general  
population and adults with current asthma.  
AUTHOR: Eisner Mark D  
CORPORATE SOURCE: Division of Occupational and Environmental Medicine,  
Department of Medicine, University of California, San  
Francisco, California, USA.. eisner@itsa.ucsf.edu  
CONTRACT NUMBER: K23 HL04201 (NHLBI)  
SOURCE: ENVIRONMENTAL HEALTH PERSPECTIVES, (2002 Aug) 110 (8)  
765-70.  
Journal code: 0330411. ISSN: 0091-6765.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200209  
ENTRY DATE: Entered STN: 20020803  
Last Updated on STN: 20020925  
Entered Medline: 20020924

AB The impact of environmental tobacco smoke (ETS) exposure on adult **pulmonary** function has not been clearly determined. Because adults with asthma have chronic airway inflammation, they may be a particularly susceptible group. Using data from the Third National Health and Nutrition Examination Survey (NHANES III), I examined the cross-sectional relationship between **serum** cotinine, a **biomarker** of ETS exposure, and **pulmonary** function among 10,581 adult nonsmokers and 440 nonsmoking adults with asthma whose cotinine and spirometry data were available. I generated residuals, which are observed minus predicted values (based on Crapo equations), for forced expiratory volume in 1 sec (**FEV1**), forced vital capacity (FVC), and **FEV1/FVC** ratio to adjust for age, sex, and height. In addition, I used multivariate linear regression to control for sociodemographic characteristics and previous smoking history. Most adults with and without asthma had detectable **serum** cotinine levels, indicating recent ETS exposure (85.7% and 83.4%, respectively). Among nonsmoking male participants, I found no evidence that ETS exposure was related to decreased **pulmonary** function. In the nonsmoking female stratum, the highest cotinine tertile was associated with a lower **FEV1** [-100 mL; 95% confidence interval (CI), -143 to -56 mL], FVC (-119 mL; 95% CI, -168 to -69 mL), and **FEV1/FVC** ratio (-1.77%; 95% CI, -2.18% to -1.36%). Among women with asthma, the highest cotinine tertile was also associated with decreased **FEV1** (-261 mL; 95% CI, -492 to -30 mL), FVC (-291 mL; 95% CI, -601 to 20 mL), and **FEV1/FVC** ratio

(-1.6%; 95% CI, -3.3% to 0.19%). In conclusion, ETS exposure is associated with decreased **pulmonary** function in adult females, especially those with asthma. This analysis should provide further impetus for public policies that promote smoke-free environments.

L16 ANSWER 2 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2002:504373 BIOSIS  
DOCUMENT NUMBER: PREV200200504373  
TITLE: Involuntary smoking and asthma severity in children: Data from the Third National Health and Nutrition Examination Survey.  
AUTHOR(S): Mannino, David M. (1); Homa, David M.; Redd, Stephen C.  
CORPORATE SOURCE: (1) National Center for Environmental Health, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS E-17, Atlanta, GA, 30333: dmannino@cdc.gov USA  
SOURCE: Chest, (August, 2002) Vol. 122, No. 2, pp. 409-415. print. ISSN: 0012-3692.  
DOCUMENT TYPE: Article  
LANGUAGE: English

AB Study objectives: We sought to determine the indicators of asthma severity among children in the United States with high and low levels of tobacco smoke exposure. Design: Cross-sectional study. Setting: Nationally representative survey of participants in the Third National Health and Nutrition Examination Survey (from 1988 to 1994). Participants: Five hundred twenty-three children with physician-diagnosed asthma. Measurements and results: We stratified the study participants into tertiles on the basis of **serum** levels of cotinine (a metabolite of nicotine that indicates tobacco smoke exposure). We used logistic and linear regression modeling, adjusting for known covariates, to determine the effect of high environmental tobacco smoke exposure on the following outcomes: asthma severity (determined using reported symptom and respiratory illness frequency); lung function; physician visits; and school absence. Among our study sample, 78.6% of children had mild asthma, 6.8% of children had moderate asthma, and 14.6% of children had severe asthma. Asthmatic children with high levels of smoke exposure, compared with those with low levels of exposure, were more likely to have moderate or severe asthma (odds ratio, 2.7 95% confidence interval (CI), 1.1 to 6.8) and decreased lung function, with a mean **FEV1** decrement of 213 mL or 8.1% (95% CI, -14.7 to -3.5). Conclusions: Involuntary smoke exposure is associated with increased asthma severity and worsened lung function in a nationally representative group of US children with asthma.

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:859774 CAPLUS  
DOCUMENT NUMBER: 136:353476  
TITLE: Surfactant protein D (SP-D) and systemic scleroderma (SSc)  
AUTHOR(S): Maeda, Manabu; Ichiki, Yoshiro; Aoyama, Yumi; Kitajima, Yasuo  
CORPORATE SOURCE: Department of Dermatology, Gifu Prefectural Hospital, Gifu, 500-8226, Japan  
SOURCE: Journal of Dermatology (2001), 28(9), 467-474  
CODEN: JDMYAG; ISSN: 0385-2407  
PUBLISHER: Japanese Dermatological Association  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The authors measured **serum** levels of SP-D in collagen diseases (110 cases) such as systemic scleroderma (SSc), scleroderma spectrum disorders (SSD), systemic lupus erythematosus (SLE), Sjogren syndrome (Sjs), dermatomyositis (DM), and rheumatoid arthritis (RA) and, as a control, dermatitis (DE) (109 cases). Addnl., the authors performed a correlation anal. to det. how these levels were related to **pulmonary** fibrosis and function test (vital capacity, %DLco). The **serum** levels of SP-D increased in SSc patients with Barnett type

III more than in SSc patients with Barnett type I or II, while they increased slightly in SSD (incomplete type of SSc) patients. The differences in these figures were statistically significant between the SSc (SSc & SSD) and non-SSc (SLE, DM, Sjs & RA) groups. The **serum** levels of SP-D in SSc patients with anti-topoisomerase I antibodies were statistically higher than those in SSc patients with other types of anti-nuclear antibodies. There was a statistically significant correlation between the severity of **pulmonary** fibrosis and the **serum** levels of SP-D, and a statistically neg. correlation between SP-D levels and vital capacity or %DLco, but there was no proportional correlation with the forced expiratory vol. (FEV1.0%). There was no statistical relation between pre- and post-therapy with photopheresis; however, there was a statistical correlation between the **serum** levels of SP-D and KL-6. In the group of collagen diseases, plasma levels of SP-D were higher than **serum** levels of SP-D. Patients with SSc possess higher levels of SP-D than do those with other collagen diseases and dermatitis, which may correspond to the severity of **pulmonary** fibrosis.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 4 MEDLINE DUPLICATE 2  
 ACCESSION NUMBER: 2000310683 MEDLINE  
 DOCUMENT NUMBER: 20310683 PubMed ID: 10853636  
 TITLE: Antioxidant nutrients and **pulmonary** function: the Third National Health and Nutrition Examination Survey (NHANES III).  
 AUTHOR: Hu G; Cassano P A  
 CORPORATE SOURCE: Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.  
 CONTRACT NUMBER: HL 45731 (NHLBI)  
 SOURCE: AMERICAN JOURNAL OF EPIDEMIOLOGY, (2000 May 15) 151 (10) 975-81.  
 Journal code: 7910653. ISSN: 0002-9262.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200006  
 ENTRY DATE: Entered STN: 20000706  
 Last Updated on STN: 20000706  
 Entered Medline: 20000623

AB Recent studies of chronic obstructive **pulmonary** disease have raised interest in its relation to nutrition. Several dietary antioxidants have been positively associated with lung function in healthy, general population samples. This study considered the separate and joint effects of vitamin C, vitamin E, beta-carotene, and selenium intake and used both dietary assessment and **serum biomarkers** of antioxidant status. The authors used data from the Third National Health and Nutrition Examination Survey comprising a sample representative of the US population in 1988-1994 (n = 18,162 subjects aged > or =17 years). Multiple linear regression analysis examined the separate and joint effects of the antioxidants on the ratio of forced expiratory volume in the first second (FEV1)/height<sup>2</sup> adjusted for covariates. Each of the dietary and **serum** antioxidant nutrients was significantly associated with FEV1. When they were considered simultaneously (dietary and **serum** variables considered in separate models), independent associations were observed for most nutrients. **Serum** beta-carotene was less positively associated with FEV1 in smokers than nonsmokers, while **serum** selenium had a stronger positive association with FEV1 in smokers. The authors found that higher levels of antioxidant nutrients are associated with better lung function. The finding that the antioxidants differ in both their overall association with lung function and in whether this association

varies by smoking status has implications for further research.

=> l5 and forced expiratory volume

L17           0 FILE CAPLUS  
L18           4 FILE MEDLINE  
L19           3 FILE EMBASE  
L20           3 FILE BIOSIS

TOTAL FOR ALL FILES

L21           10 L5 AND FORCED EXPIRATORY VOLUME

=> dup rem

ENTER L# LIST OR (END):l21

PROCESSING COMPLETED FOR L21

L22           4 DUP REM L21 (6 DUPLICATES REMOVED)

=> l5 and adhesion

L23           2 FILE CAPLUS  
L24           0 FILE MEDLINE  
L25           0 FILE EMBASE  
L26           0 FILE BIOSIS

TOTAL FOR ALL FILES

L27           2 L5 AND ADHESION

=> dup rem

ENTER L# LIST OR (END):l27

PROCESSING COMPLETED FOR L27

L28           2 DUP REM L27 (0 DUPLICATES REMOVED)

=> d l28 ibib abs total

L28 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:       2001:49174 CAPLUS

DOCUMENT NUMBER:       135:151556

TITLE:                Elevated levels of soluble **adhesion**  
                      molecules in **sera** and BAL fluid of  
                      individuals infected with human T-cell lymphotropic  
                      virus type 1

AUTHOR(S):            Seki, Masafumi; Higashiyama, Yasuhito; Kadota,  
                      Jun-ichi; Mukae, Hiroshi; Yanagihara, Katsunori;  
                      Tomono, Kazunori; Kohno, Shigeru

CORPORATE SOURCE:     Second Department of Internal Medicine, Nagasaki  
                      University School of Medicine, Nagasaki, 852-8501,  
                      Japan

SOURCE:              Chest (2000), 118(6), 1754-1761

CODEN: CHETBF; ISSN: 0012-3692

PUBLISHER:            American College of Chest Physicians

DOCUMENT TYPE:        Journal

LANGUAGE:             English

AB   T-lymphocytic alveolitis and increased levels of interleukin-2  
      receptor-.alpha. (CD25)-bearing T cells in the BAL fluid (BALF) of human  
      T-cell lymphotropic virus type 1 (HTLV-1) carriers have been reported.  
      Several chemokines and **adhesion** mols. may contribute to the  
      accumulation of T lymphocytes in the lungs of HTLV-1 carriers. To clarify  
      the correlation between **adhesion** mols. and HTLV-1-assocd.  
      **pulmonary** disorders, the authors compared the distribution of  
      T-lymphocyte subsets and sol. **adhesion** mols., including sol.  
      intercellular **adhesion** mol. (sICAM)-1, sol. vascular cell  
      **adhesion** mol.-1 (sVCAM-1), sol. L-selectin (sL-selectin), sol.  
      E-selectin (sE-selectin), and sol. P-selectin (sP-selectin), in BALF and  
      peripheral blood, between HTLV-1 carriers and noninfected healthy  
      subjects. Flow cytometric anal. with monoclonal antibodies to

cell-surface antigens was used to identify T-lymphocyte subsets in BALF samples from HTLV-1 carriers and noninfected healthy control subjects. The levels of various sol. **adhesion** mols. in **serum** and in BALF were estd. by ELISA. Higher percentages of CD3+ cells, CD3-expressing human leukocyte antigen-DR antigen, and CD3+CD25+ cells were detected in the BALF of HTLV-1 carriers than in that of noninfected control subjects. The concns. of sICAM-1, sVCAM-1, sL-selectin, sE-selectin, and sP-selectin in the **sera** of patients were higher than in noninfected healthy control subjects. The concn. of sICAM-1 in the BALF of patients was higher than in noninfected healthy control subjects, and the concn. of sICAM-1 correlated well with the percentage of CD3+CD25+ cells. The concns. of **adhesion** mols. in the **sera** of and sICAM-1 in the BALF of HTLV-1 carriers were higher than those in noninfected individuals, and the concn. of sICAM-1 correlated well with the percentage of CD3+CD25+ cells in BALF. The authors' results suggest a possible interaction between activated T cells bearing CD25 and sol. **adhesion** mols., esp. sICAM-1, which may contribute to the **pulmonary** involvement in HTLV-1 carriers.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:6076 CAPLUS

DOCUMENT NUMBER: 134:26321

TITLE: A study of the pathogenesis in **pulmonary** asbestosis assessed by **serum** surfactant protein A and **serum** soluble intercellular **adhesion** molecule-1

AUTHOR(S): Okamoto, Yukinori

CORPORATE SOURCE: Second Dep. Intern. Med., Nara Med. Univ., Japan

SOURCE: Journal of Nara Medical Association (2000), 51(5), 257-268

CODEN: JNMAFJ

PUBLISHER: Nara Medical Association

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Surfactant protein A (SP-A) and intercellular **adhesion** mol.-1 (ICAM-1) were recently reported to be assocd. with fibrotic changes in **pulmonary** diseases. Inhaled asbestos induces **pulmonary** fibrosis leading to asbestosis. To evaluate the possible roles for the development of asbestosis, the **serum** levels of SP-A and sICAM-1 were measured and compared among workers exposed to asbestos (29 patients with asbestosis (PWAs), 50 asbestos-exposed workers without asbestosis (AEWs)), and 51 healthy controls (HCs). The mean **serum** levels of SP-A were significantly higher in PWAs (53.2+-.33.4 ng/mL) and AEWs (45.1+-.30.2 ng/mL) than that in HCs (28.8+-.10.6 ng/mL). The mean **serum** levels of SP-A in smoking population of AEWs and HCs were significantly higher than those in non-smoking AEWs and HCs. The mean **serum** levels of SP-A in smokers were significantly higher in PWAs and AEWs than in HCs. The mean **serum** levels of SP-A in non-smokers were significantly higher in PWAs than in HCs. The mean **serum** levels of sol. ICAM-1 (sICAM-1) were significantly higher in PWAs (270.2+-.114.8 ng/mL) and AEWs (250.7+-.80.5 ng/mL) than in HCs (152.2+-.49.9 ng/mL). The mean **serum** levels of sICAM-1 in AEWs were significantly higher in smokers than in non-smokers. The mean **serum** levels of sICAM-1 in smokers were significantly higher in PWAs and AEWs than in HCs. The mean **serum** levels of sICAM-1 in non-smokers were significantly higher in PWAs and AEWs than in HCs. The **serum** levels of SP-A were significantly correlated with the **serum** levels of sICAM-1 in PWAs and AEWs. In conclusion, the present study suggests that asbestos exposure is independently related to the elevation of **serum** levels of both SP-A and sICAM-1 and that this elevation is assocd. with the development of asbestosis. SP-A and sICAM-1 can be useful markers in detecting early asbestos-related

disorders.

=> s (pulmonary or lung) and (biomarker or marker) and (urine or serum)

L29 1128 FILE CAPLUS  
L30 2887 FILE MEDLINE  
L31 2236 FILE EMBASE  
L32 2479 FILE BIOSIS

TOTAL FOR ALL FILES

L33 8730 (PULMONARY OR LUNG) AND (BIOMARKER OR MARKER) AND (URINE OR SERUM)

=> 133 and cadherin

L34 6 FILE CAPLUS  
L35 4 FILE MEDLINE  
L36 4 FILE EMBASE  
L37 4 FILE BIOSIS

TOTAL FOR ALL FILES

L38 18 L33 AND CADHERIN

=> 138 and FEV1

L39 0 FILE CAPLUS  
L40 0 FILE MEDLINE  
L41 0 FILE EMBASE  
L42 0 FILE BIOSIS

TOTAL FOR ALL FILES

L43 0 L38 AND FEV1

=> dup rem

ENTER L# LIST OR (END):138

PROCESSING COMPLETED FOR L38

L44 12 DUP REM L38 (6 DUPLICATES REMOVED)

=> d 144 ibib abs total

L44 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:716605 CAPLUS

DOCUMENT NUMBER: 137:213277

TITLE: Cell-based detection and differentiation of disease states

INVENTOR(S): Pressman, Norman J.; Hirsch, Kenneth S.

PATENT ASSIGNEE(S): Monogen, Inc, USA; McCall, John, Douglas

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002073204	A2	20020919	WO 2002-GB1125	20020312
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2001-274638P P 20010312

AB The present invention is directed to a panel for detecting a generic disease state or discriminating between specific disease states using cell-based diagnosis. The panel comprises a plurality of probes each of which specifically binds to a **marker** assocd. with a generic or specific disease state, wherein the pattern of binding of the component probes of the panel to cells in a cytol. specimen is diagnostic of the presence or specific nature of said disease state. The present invention is also directed to a method of forming a panel for detecting a disease state or discriminating between disease states in a patient using cell-based diagnosis. The method involves detg. the sensitivity and specificity of binding of probes each of which specifically binds to a member of a library of **markers** assocd. with a disease state and selecting a limited plurality of said probes whose pattern of binding is diagnostic for the presence or specific nature of said disease state. The present method is also directed to a method of detecting a disease or discriminating between disease states comprising. The method involves contacting a cytol. sample suspected of contg. abnormal cells characteristic of a disease state with a panel according to claim 1 and detecting a pattern of binding of said probes that is diagnostic for the presence or specific nature of said disease state.

L44 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:172151 CAPLUS

DOCUMENT NUMBER: 136:230707

TITLE: Detection of aberrant promoter methylation by methylation-specific nested PCR in predicting cancer risk

INVENTOR(S): Belinsky, Steven A.; Palmisano, William A.

PATENT ASSIGNEE(S): Lovelace Respiratory Research Institute, USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018649	A1	20020307	WO 2001-US26452	20010824
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

AU 2001088379 A5 20020313

AU 2001-88379 20010824

PRIORITY APPLN. INFO.:

US 2000-228057P P 20000825

WO 2001-US26452 W 20010824

AB A mol. **marker**-based method for monitoring and detecting cancer in humans. Aberrant methylation of gene promoters is a **marker** for cancer risk in humans. A two-stage, or "nested" polymerase chain reaction method is disclosed for detecting methylated DNA sequences at sufficiently high levels of sensitivity to permit cancer screening in biol. fluid samples, such as sputum, obtained non-invasively. The method is for detecting the aberrant methylation of the p16 gene, O 6 -methylguanine-DNA methyltransferase gene, Death-assocd. protein kinase gene, RAS-assocd. family 1 gene, or other gene promoters. The method offers a potentially powerful approach to population-based screening for the detection of **lung** and other cancers. Detection of one methylated allele in a mixt. contg. >50,000 methylated alleles is



demonstrated.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:937303 CAPLUS

DOCUMENT NUMBER: 138:20443

TITLE: Endocrine disruptor screening using DNA chips of endocrine disruptor-responsive genes

INVENTOR(S): Kondo, Akihiro; Takeda, Takeshi; Mizutani, Shigetoshi; Tsujimoto, Yoshimasa; Takashima, Ryokichi; Enoki, Yuki; Kato, Ikunoshin

PATENT ASSIGNEE(S): Takara Bio Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 386 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002355079	A2	20021210	JP 2002-69354	20020313
PRIORITY APPLN. INFO.:			JP 2001-73183	A 20010314
			JP 2001-74993	A 20010315
			JP 2001-102519	A 20010330

AB A method and kit for detecting endocrine-disrupting chems. using DNA microarrays are claimed. The method comprises prepg. a nucleic acid sample contg. mRNAs or cDNAs originating in cells, tissues, or organisms which have been brought into contact with a sample contg. the endocrine disruptor. The nucleic acid sample is hybridized with DNA microarrays having genes affected by the endocrine disruptor or DNA fragments originating in these genes have been fixed. The results obtained are then compared with the results obtained with the control sample to select the gene affected by the endocrine disruptor. Genes whose expression is altered by tri-Bu tin, 4-octaphenol, 4-nonylphenol, di-N-Bu phthalate, dichlorohexyl phthalate, octachlorostyrene, benzophenone, diethylhexyl phthalate, diethylstilbestrol (DES), and 17-.beta. estradiol (E2), were found in mice by DNA chip anal.

L44 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:787469 CAPLUS

DOCUMENT NUMBER: 137:368150

TITLE: Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients

AUTHOR(S): Abe, Hironori; Kuroki, Motomu; Imakiire, Takayuki; Yamauchi, Yasushi; Yamada, Hiromi; Arakawa, Fumiko; Kuroki, Masahide

CORPORATE SOURCE: Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, 814-0180, Japan

SOURCE: Journal of Immunological Methods (2002), 270(2), 227-233

CODEN: JIMMBG; ISSN: 0022-1759

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The MK-1 antigen, also termed as Ep-CAM, is a membrane glycoprotein that is overexpressed on the majority of tumor cells of epithelial origin and thereby can be used as a target of immunodetection and immunotherapy of cancer. It has previously been shown that several type-I transmembrane proteins, including E-cadherin, ErbB-2 and intercellular adhesion mol.-1 (ICAM-1), may be useful as tumor markers because

they are released into the circulation of many cancer patients. To address the question of whether MK-1, the same type-I membrane protein, is also released into the **sera**, we developed a sandwich-type ELISA system by prepg. a recombinant MK-1 protein and two anti-MK-1 monoclonal antibodies with different epitope specificities. Using this ELISA, we found that the MK-1 levels in **serum** samples from healthy volunteers were all less than 2 ng/mL, whereas the Mk-1 levels in **sera** of about 10% of patients with malignant tumors of various tissue origins were increased to 2-78 ng/mL, indicating that MK-1 is released from tumor cells into the circulation under certain conditions. These findings should be borne in mind when trying to perform passive antibody therapy for cancer using anti-MK-1 antibody.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:863850 CAPLUS

DOCUMENT NUMBER: 136:32755

TITLE: Nucleic acid compositions, kits, and methods for identification, assessment, prevention, and therapy of human breast cancer

INVENTOR(S): Lillie, James; Palermo, Adam; Wang, Youzhen; Steinmann, Kathleen; Elias, Josh

PATENT ASSIGNEE(S): Millennium Predictive Medicine, Inc., USA

SOURCE: PCT Int. Appl., 2674 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046697	A2	20010628	WO 2000-US35214	20001221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR				

PRIORITY APPLN. INFO.:  
 US 1999-PV171406 19991221  
 US 2000-PV176423 20000114  
 US 2000-PV190471 20000317  
 US 2000-PV193482 20000329  
 US 2000-PV205231 20000515  
 US 2000-PV213236 20000620  
 US 2000-PV219865 20000720

AB The invention relates to nucleic acid **marker** compns., kits and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of **markers** are provided, wherein changes in the levels of expression of one or more of the nucleic acid **markers** is correlated with the presence of breast cancer. The level of expression of numerous potential **markers** was measured in cells obtained from breast cancer tissue samples obtained from fifteen patients afflicted with breast cancer and from eleven breast cancer cell cultures, based on comparison with expression levels of each **marker** in corresponding non-cancerous breast tissue and cell cultures. The 15 cancer tissue samples include (i) five invasive lobular carcinomas (ILC), (ii) five invasive ductal carcinomas (IDC), and (iii) five samples of ductal carcinoma in situ (DCIS). As an addnl. evaluation of ability to indicate breast cancer, individual **markers** that were identified by transcriptional profiling criteria were also tested in six different subtracted library expts. In addn., protein profiling

expts. were undertaken to assess whether the proteins assocd. with the expression of individual **markers** of the invention are secreted. Table 21 lists approx. 43,500 GenBank Accession Nos. from the present invention. [This abstr. record is one of 8 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

L44 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001:338762 CAPLUS  
 DOCUMENT NUMBER: 134:362292  
 TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile  
 INVENTOR(S): Farr, Spencer  
 PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA  
 SOURCE: PCT Int. Appl., 222 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-165398P	P 19991105
			US 2000-196571P	P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

L44 ANSWER 7 OF 12 MEDLINE DUPLICATE 1  
 ACCESSION NUMBER: 2000487884 MEDLINE  
 DOCUMENT NUMBER: 20489842 PubMed ID: 11038142  
 TITLE: Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.  
 COMMENT: Comment in: Cancer J. 2000 Jul-Aug;6(4):213-4

AUTHOR: Tso C L; McBride W H; Sun J; Patel B; Tsui K H; Paik S H; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A  
CORPORATE SOURCE: Department of Urology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, USA.  
SOURCE: CANCER JOURNAL, (2000 Jul-Aug) 6 (4) 220-33.  
Journal code: 100931981. ISSN: 1528-9117.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200102  
ENTRY DATE: Entered STN: 20010322  
Last Updated on STN: 20010322  
Entered Medline: 20010208

AB PURPOSE: The mechanism of progression of human prostate cancer (CaP) cells under androgen ablation therapy remains unclear. To study the alternative pathways of CaP cell growth under conditions of androgen deprivation, androgen-independent CaP variants were selected and expanded from an androgen-dependent CaP line via an in vitro androgen deprivation treatment. Cellular and molecular properties of these androgen-independent variants were characterized both in vitro and in vivo and compared with those of their parental androgen-dependent cells. METHODS: Androgen deprivation treatment of an androgen-dependent CaP cell line, LNCaP, was carried out by replacing culture medium with RPMI 1640 medium plus 10% charcoal-stripped **serum**. Cells that survived through the androgen deprivation treatment were harvested and expanded in the androgen-deficient culture medium and were designated CL-1. The CL-1 cells were also recultured in androgen-containing medium and designated CL-2. The growth (cell cycle analysis, 3H-thymidine incorporation assay, growth expansion, and colonization efficiency), expression of CaP-associated **markers** (semiquantitative reverse transcriptase polymerase chain reaction), interaction with endothelial and bone marrow stromal cells, sensitivity to anticancer agents and radiation (growth inhibition), and tumorigenicity of CL-1 and CL-2 cells were determined and compared with these characteristics in parental LNCaP cells. RESULTS: CL-1 and CL-2 cells are fast-growing cells when compared with parental LNCaP cells. They were capable of potentiating the growth of endothelial and bone marrow stromal cells in co-culture experiments and acquired significant resistance to radiation and to anticancer cytotoxic agents (Taxol paclitaxel, vinblastine, and etoposide). In contrast to the poorly tumorigenic parental LNCaP cells, CL-1 and CL-2 lines proved highly tumorigenic, exhibiting invasive and metastatic characteristics in intact and castrated mice or in female mice within a short period of 3 to 4 weeks. No growth supplements (e.g., Matrigel) were needed. When transfected with the green fluorescence protein (GFP) gene and transplanted orthotopically in the accessory sex gland, extensive metastatic disease from the primary CL tumor could be identified in bone, lymph nodes, **lung**, liver, spleen, kidney, and brain. Semiquantitative reverse transcriptase polymerase chain reaction analysis revealed a markedly distinct molecular expression profile in the CL lines: overexpression of basic fibroblast growth factor, interleukin-6, interleukin-8, vascular endothelial growth factor, transforming growth factor-beta, epidermal growth factor receptor, caveolin, and bcl-2 messenger RNAs and marked down-regulation of E-cadherin, p-53, and pentaerythritol tetranitrate. CONCLUSIONS: Early administration of hormonal therapy after failure of first-line treatment is associated with a profound clonal selection of aggressive AI variants, such as CL-1 and CL-2 lines. These tumor lines, with their parental counterparts, can serve as valuable tools for studying the cellular and molecular mechanisms of CaP progression and metastasis under hormonal therapy. CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate cancer.

L44 ANSWER 8 OF 12 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
 ACCESSION NUMBER: 2000405403 EMBASE  
 TITLE: Molecular **markers** for early cancer detection.  
 AUTHOR: Ahmed F.E.  
 CORPORATE SOURCE: F.E. Ahmed, Department of Radiation Oncology, Leo W. Jenkins Cancer Center, Brody School of Medicine, Greenville, NC 27858, United States  
 SOURCE: Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews, (2000) 18/2 (75-125).  
 Refs: 357  
 ISSN: 1059-0501 CODEN: JSHREB  
 COUNTRY: United States  
 DOCUMENT TYPE: Journal; General Review  
 FILE SEGMENT: 016 Cancer  
 017 Public Health, Social Medicine and Epidemiology  
 029 Clinical Biochemistry  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English

AB Uncontrolled cell proliferation is the hallmark of cancer, and tumor cells typically have acquired damage to genes that directly regulate their cell cycles (4). Interplay between the products of the cyclin D1, p16(INKA4) and retinoblastoma (Rb) susceptibility genes is involved in the regulation of cell cycle progression from G1 to S. Cell progression from G1 to S requires, among other things, activation of specific kinases, Cdks (Cdk4 and Cdk6), in association with cyclin D1. The active Cdk/cyclin D1 complex phosphorylates sequentially the Rb protein, thus releasing Rb-bound transcription factors of the E2F family. Free E2Fs transactivate genes that are essential for entry into S and DNA replication (S-phase effectors). Cdk/cyclin D1 activity is negatively regulated by binding of several cyclin kinase inhibitors, including p16(INKA4). The p16(INKA4) is believed to be activated in response to growth control stimuli through pathways which are not fully elucidated. Because pRb, cyclin D1 and p16(INKA4) are all upstream regulators of E2f activity, the frequent involvement of these proteins in human cancer suggests a central role for E2F in control of cell proliferation (9). Genetic alterations affecting p16(INKA4) and cyclin D1 protein that govern phosphorylation of the Rb protein and control exit from the G1 phase of the cell cycle, are so frequent in human cancers that inactivation of this pathway may well be necessary for tumor development. Like the p53 protein, component of this Rb pathway, although not essential for the cell per se, may participate in checkpoint functions that regulate homeostatic tissue renewal through life (10). It was recently recognized that the regulation of cell death (apoptosis) is also an important modulator of tumorigenesis. At least two genes linked to human cancers, bcl-2 and TP53, have been shown to regulate apoptosis. Cell culture studies have demonstrated that TP53 can induce, and bcl-2 suppress apoptosis in response to various stimuli. This raises the question as to how dysregulation of apoptosis contributes to neoplastic transformation and malignant cell growth (11). Genes for all these **markers** have been identified, isolated and sequenced, making it possible to apply molecular-based technologies for cancer detection. The continued acceleration of development of scientific information and new techniques necessitates the need for clinical application. Research in molecular genetics, cell biology, protein chemistry and immunology has identified many early changes occurring during neoplastic progression such as novel proteins, growth factors, cytokines, DNA damage and multiple genetic alterations. These changes present in tissue and other body fluids (e.g., plasma, **urine**, sputum, **lung** washings and feces) are now recognized as **markers** for impending cancer or for risk of cancer development. To explore fully the application of molecular profiles for earlier detection and risk assessment, it is essential to understand the molecular pathogenesis of cancer (i.e., the natural history of tumor progression) so that the biological behavior of an evolving lesion can be predicted with

SOURCE: Maryland 21287-6917, USA.  
 AMERICAN JOURNAL OF SURGICAL PATHOLOGY, (1998 Nov) 22 (11)  
 1393-403.  
 Journal code: 7707904. ISSN: 0147-5185.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199811  
 ENTRY DATE: Entered STN: 19990106  
 Last Updated on STN: 19990106  
 Entered Medline: 19981119

AB This report describes the clinicopathologic and immunohistochemical features of 14 cases of epithelioid trophoblastic tumor (ETT), a distinctive but rare gestational trophoblastic tumor. The patients with this neoplasm were in the reproductive age group and presented with abnormal vaginal bleeding. Although diagnosis was usually associated with a gestational event, the latter was sometimes remote. Two of the 14 patients presented with extrauterine ETT without evidence of prior gestational trophoblastic disease in the uterus. **Serum** human chorionic gonadotropin levels were elevated in eight of nine patients in whom this information was available. In the uterus, ETT presented as a discrete, hemorrhagic, solid and cystic lesion that was located either in the fundus, lower uterine segment, or endocervix. Microscopically, the tumor was composed of a relatively uniform population of mononucleate intermediate trophoblastic cells forming nests and solid masses. The cells resemble the trophoblastic cells in the chorion laeve, and we have therefore designated them "chorionic-type intermediate trophoblast." Typically, islands of trophoblastic cells were surrounded by extensive necrosis and were associated with a hyaline-like matrix creating a "geographic" pattern that is quite characteristic of this lesion. The mean mitotic count was two mitoses per 10 high-power fields, and the average Ki-67 nuclear labeling index was 18%. Immunohistochemically, all cases were diffusely positive for inhibin-alpha, cytokeratin (AE1/AE3), epithelial membrane antigen, E-cadherin, prolyl 4-hydroxylase, and epidermal growth factor receptor but were only focally immunoreactive for human placental lactogen, human chorionic gonadotropin, PLAP, and Mel-CAM. The monomorphic growth pattern of ETT resembles placental site trophoblastic tumor to a much greater degree than choriocarcinoma which is characterized by a dimorphic population of trophoblast. In contrast to placental site trophoblastic tumor, the cells of ETT are smaller and display less nuclear pleomorphism. In addition, ETT grows in a nodular fashion compared with the infiltrative pattern of placental site trophoblastic tumor. In some of the cases, the trophoblastic cells in ETT replaced the endocervical surface epithelium, giving the appearance that the tumor was derived from the cervix. Moreover, because the associated hyaline-like material in ETT resembles keratin, the tumor can be misinterpreted as a keratinizing squamous cell carcinoma of the cervix. Ten patients underwent total hysterectomy and two had an endometrial curettage only. The two patients who presented with extrauterine ETT underwent small bowel resection and **lung** resection. Two of 12 patients with ETT in the uterus developed metastasis in the **lungs** and bone. One of these patients is alive with disease at 43 months and one patient was lost to follow-up after 2 months. One of the two patients who had extrauterine disease died of widespread tumor 36 months after diagnosis. The remainder of the patients are alive and well from 1 to 120 months. In summary, ETT is a rare trophoblastic tumor that simulates carcinoma and can behave in a malignant fashion. It appears to be less aggressive than choriocarcinoma, more closely resembling the behavior of placental site trophoblastic tumor. Based on the morphologic and immunohistochemical features, it appears that ETT develops from neoplastic transformation of chorionic-type intermediate trophoblast.

(-1.6%; 95% CI, -3.3% to 0.19%). In conclusion, ETS exposure is associated with decreased **pulmonary** function in adult females, especially those with asthma. This analysis should provide further impetus for public policies that promote smoke-free environments.

L16 ANSWER 2 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 2002:504373 BIOSIS  
DOCUMENT NUMBER: PREV200200504373  
TITLE: Involuntary smoking and asthma severity in children: Data from the Third National Health and Nutrition Examination Survey.  
AUTHOR(S): Mannino, David M. (1); Homa, David M.; Redd, Stephen C.  
CORPORATE SOURCE: (1) National Center for Environmental Health, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS E-17, Atlanta, GA, 30333: dmannino@cdc.gov USA  
SOURCE: Chest, (August, 2002) Vol. 122, No. 2, pp. 409-415. print. ISSN: 0012-3692.  
DOCUMENT TYPE: Article  
LANGUAGE: English

AB Study objectives: We sought to determine the indicators of asthma severity among children in the United States with high and low levels of tobacco smoke exposure. Design: Cross-sectional study. Setting: Nationally representative survey of participants in the Third National Health and Nutrition Examination Survey (from 1988 to 1994). Participants: Five hundred twenty-three children with physician-diagnosed asthma. Measurements and results: We stratified the study participants into tertiles on the basis of **serum** levels of cotinine (a metabolite of nicotine that indicates tobacco smoke exposure). We used logistic and linear regression modeling, adjusting for known covariates, to determine the effect of high environmental tobacco smoke exposure on the following outcomes: asthma severity (determined using reported symptom and respiratory illness frequency); lung function; physician visits; and school absence. Among our study sample, 78.6% of children had mild asthma, 6.8% of children had moderate asthma, and 14.6% of children had severe asthma. Asthmatic children with high levels of smoke exposure, compared with those with low levels of exposure, were more likely to have moderate or severe asthma (odds ratio, 2.7 95% confidence interval (CI), 1.1 to 6.8) and decreased lung function, with a mean **FEV1** decrement of 213 mL or 8.1% (95% CI, -14.7 to -3.5). Conclusions: Involuntary smoke exposure is associated with increased asthma severity and worsened lung function in a nationally representative group of US children with asthma.

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:859774 CAPLUS  
DOCUMENT NUMBER: 136:353476  
TITLE: Surfactant protein D (SP-D) and systemic scleroderma (SSc)  
AUTHOR(S): Maeda, Manabu; Ichiki, Yoshiro; Aoyama, Yumi; Kitajima, Yasuo  
CORPORATE SOURCE: Department of Dermatology, Gifu Prefectural Hospital, Gifu, 500-8226, Japan  
SOURCE: Journal of Dermatology (2001), 28(9), 467-474  
CODEN: JDMYAG; ISSN: 0385-2407  
PUBLISHER: Japanese Dermatological Association  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The authors measured **serum** levels of SP-D in collagen diseases (110 cases) such as systemic scleroderma (SSc), scleroderma spectrum disorders (SSD), systemic lupus erythematosus (SLE), Sjogren syndrome (Sjs), dermatomyositis (DM), and rheumatoid arthritis (RA) and, as a control, dermatitis (DE) (109 cases). Addnl., the authors performed a correlation anal. to det. how these levels were related to **pulmonary** fibrosis and function test (vital capacity, %DLco). The **serum** levels of SP-D increased in SSc patients with Barnett type